Patents by Inventor Claire Lankin

Claire Lankin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES
    Publication number: 20220281886
    Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 8, 2022
    Applicant: Merck Sharp Dohme Corp.
    Inventors: Frank Bennett, Jason E. Imbriglio, Angela D. Kerekes, Tanweer Khan, Claire Lankin, Derun Li, Zhicai Wu, Yusheng Xiong, Hyewon Youm, Yang Yu, Feng Ye, Anthappan Tony Kurissery, Venukrishnan Komanduri
  • NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES
    Publication number: 20220273669
    Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 1, 2022
    Applicant: Merck Sharp Dohme Corp.
    Inventors: Qingmei Hong, Jason E. Imbriglio, Angela D. Kerekes, Tanweer Khan, Claire Lankin, Derun Li, Rui Liang, Pengcheng Patrick Shao, Zhicai Wu, Yusheng Xiong, Feng Ye, Hyewon Youm, Yang Yu, Anthappan Tony Kurissery, Venukrishnan Komanduri
  • Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
    Patent number: 10414775
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John P. Caldwell, Mary Ann Caplen, Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Claire Lankin, Derun Li, Hong Liu, Amy McCracken, Brian McKittrick, Ashwin Rao, Jayaram Tagat, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu, Tianyuan Zhang
  • COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE
    Publication number: 20190218224
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.
    Type: Application
    Filed: August 10, 2017
    Publication date: July 18, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John P. Caldwell, Mary Ann Caplen, Jared N. Cumming, Kevin D. Dykstra, Alan Hruza, Claire Lankin, Derun Li, Hong Liu, Amy McCracken, Brian McKittrick, Ashwin Rao, Jayaram Tagat, Haiqun Tang, Brandon M. Taoka, Andreas Verras, Shawn P. Walsh, Wen-Lian Wu, Tianyuan Zhang
  • Factor IXa inhibitors
    Patent number: 9161924
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: October 20, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig Boyle, William Greenlee, Samuel Chackalamannil, Claire Lankin
  • FACTOR IXA INHIBITORS
    Publication number: 20140219989
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: July 3, 2012
    Publication date: August 7, 2014
    Inventors: Craig Boyle, William Greenlee, Samuel Chackalamannil, Claire Lankin
  • 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    Publication number: 20070066620
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.
    Type: Application
    Filed: September 15, 2006
    Publication date: March 22, 2007
    Inventors: Bernard Neustadt, Craig Boyle, Samuel Chackalamannil, Joel Harris, Claire Lankin, Hong Liu, Unmesh Shah, Andrew Stamford